Constitutive expression of SOCS3 confers resistance to IFN-α in chronic myelogenous leukemia cells

被引:91
作者
Sakai, I [1 ]
Takeuchi, K [1 ]
Yamauchi, H [1 ]
Narumi, H [1 ]
Fujita, S [1 ]
机构
[1] Ehime Univ, Sch Med, Dept Internal Med 1, Shigenobu, Ehime 7910925, Japan
关键词
D O I
10.1182/blood-2002-01-0073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because suppressor of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that aberrant SOCS expression confers resistance against cytokine therapy. This study reports on the constitutive expression of SOCS3 in most chronic myelogenous leukemia (CML) cell lines, which are resistant to treatment with interferon alpha (IFN-alpha). In contrast, the KT-1/A3 cell line, in which constitutive expression of SOCS3 is barely detectable, is sensitive to IFN-alpha treatment. Forced expression of SOCS3 in the KT-1/A3 cell line confers resistance to IFN-alpha. treatment. Furthermore, most of the blast cells from patients in CIVIL blast crisis, which are usually resistant to IFN-alpha therapy, showed constitutive expression of SOCS3. These findings indicate that constitutive SOCS3 expression affects the IFN-alpha sensitivity of CML cell lines and blast cells from patients with CML blast crisis.
引用
收藏
页码:2926 / 2931
页数:6
相关论文
共 37 条
[1]   Autoregulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter [J].
Auernhammer, CJ ;
Bousquet, C ;
Melmed, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6964-6969
[2]   STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma [J].
Brender, C ;
Nielsen, M ;
Kaltoft, K ;
Mikkelsen, G ;
Zhang, Q ;
Wasik, M ;
Billestrup, N ;
Odum, N .
BLOOD, 2001, 97 (04) :1056-1062
[3]  
BROXMEYER HE, 1983, J IMMUNOL, V131, P1300
[4]   Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl [J].
Carlesso, N ;
Frank, DA ;
Griffin, JD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :811-820
[5]   SOCS proteins, regulators of intracellular signaling [J].
Chen, XP ;
Losman, JA ;
Rothman, P .
IMMUNITY, 2000, 13 (03) :287-290
[6]  
Cohney SJ, 1999, MOL CELL BIOL, V19, P4980
[7]   JAK-STAT PATHWAYS AND TRANSCRIPTIONAL ACTIVATION IN RESPONSE TO IFNS AND OTHER EXTRACELLULAR SIGNALING PROTEINS [J].
DARNELL, JE ;
KERR, IM ;
STARK, GR .
SCIENCE, 1994, 264 (5164) :1415-1421
[8]   A new protein containing an SH2 domain that inhibits JAK kinases [J].
Endo, TA ;
Masuhara, M ;
Yokouchi, M ;
Suzuki, R ;
Sakamoto, H ;
Mitsui, K ;
Matsumoto, A ;
Tanimura, S ;
Ohtsubo, M ;
Misawa, H ;
Miyazaki, T ;
Leonor, N ;
Taniguchi, T ;
Fujita, T ;
Kanakura, Y ;
Komiya, S ;
Yoshimura, A .
NATURE, 1997, 387 (6636) :921-924
[9]   THE PROTEINS OF ISGF-3, THE INTERFERON ALPHA-INDUCED TRANSCRIPTIONAL ACTIVATOR, DEFINE A GENE FAMILY INVOLVED IN SIGNAL TRANSDUCTION [J].
FU, XY ;
SCHINDLER, C ;
IMPROTA, T ;
AEBERSOLD, R ;
DARNELL, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7840-7843
[10]   RECOMBINANT INTERFERON-ALPHA-2C IN CHRONIC MYELOGENOUS LEUKEMIA - RELATIONSHIP OF SENSITIVITY OF COMMITTED HEMATOPOIETIC PRECURSOR CELLS-INVITRO (BFU-E, CFU-GM, CFU-MEG) AND CLINICAL-RESPONSE [J].
GEISSLER, D ;
GASTL, G ;
AULITZKY, W ;
TILG, H ;
GAGGL, S ;
KONWALINKA, G ;
HUBER, C .
LEUKEMIA RESEARCH, 1990, 14 (07) :629-636